{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Proteinuria&page=7",
    "query": {
      "condition": "Proteinuria",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 193,
    "total_pages": 20,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Proteinuria&page=8&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Proteinuria&page=6&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-20T18:44:25.019Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07348718",
      "title": "Rubix LS Diabetic Kidney Disease (DKD) Registry Study",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diabetic Kidney Disease (DKD)"
      ],
      "interventions": [
        {
          "name": "Kidney-Protective Therapies Used in Routine Care",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rubix LS",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 2000,
      "start_date": "2025-12-15",
      "completion_date": "2026-04-01",
      "has_results": false,
      "last_update_posted_date": "2026-01-16",
      "last_synced_at": "2026-10-20T18:44:25.019Z",
      "location_count": 1,
      "location_summary": "Lawrence, Massachusetts",
      "locations": [
        {
          "city": "Lawrence",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07348718"
    },
    {
      "nct_id": "NCT00920764",
      "title": "A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Treated With Renin-Angiotensin System Inhibitors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Kidney Disease",
        "Diabetic Nephropathy"
      ],
      "interventions": [
        {
          "name": "Placebo for Atrasentan 0.2 mg/mL solution",
          "type": "DRUG"
        },
        {
          "name": "0.25 mg Atrasentan QD",
          "type": "DRUG"
        },
        {
          "name": "0.75 mg Atrasentan QD",
          "type": "DRUG"
        },
        {
          "name": "1.75 mg Atrasentan QD",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie (prior sponsor, Abbott)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 92,
      "start_date": "2009-06",
      "completion_date": "2010-05",
      "has_results": false,
      "last_update_posted_date": "2018-06-06",
      "last_synced_at": "2026-10-20T18:44:25.019Z",
      "location_count": 24,
      "location_summary": "Tempe, Arizona • Azusa, California • Los Angeles, California + 16 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Azusa",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00920764"
    },
    {
      "nct_id": "NCT01404910",
      "title": "Removal of Anti-Angiogenic Proteins in Preeclampsia Before Delivery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Preeclampsia"
      ],
      "interventions": [
        {
          "name": "Apheresis using Liposorber LA-15 System",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 11,
      "start_date": "2013-05",
      "completion_date": "2015-09",
      "has_results": false,
      "last_update_posted_date": "2017-03-16",
      "last_synced_at": "2026-10-20T18:44:25.019Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01404910"
    },
    {
      "nct_id": "NCT01103778",
      "title": "Pilot Study of Velcade® in IgA Nephropathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Chronic Kidney Disease",
        "IgA Nephropathy"
      ],
      "interventions": [
        {
          "name": "Bortezomib (Velcade®)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Rogosin Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2010-07",
      "completion_date": "2017-04-17",
      "has_results": true,
      "last_update_posted_date": "2018-11-16",
      "last_synced_at": "2026-10-20T18:44:25.019Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01103778"
    },
    {
      "nct_id": "NCT06466135",
      "title": "Study of WAL0921 in Patients With Glomerular Kidney Diseases",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Nephropathies",
        "Primary Focal Segmental Glomerulosclerosis",
        "Minimal Change Disease",
        "Primary Immunoglobulin A Nephropathy",
        "Primary Membranous Nephropathy"
      ],
      "interventions": [
        {
          "name": "WAL0921",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Walden Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 96,
      "start_date": "2024-07-02",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-08-03",
      "last_synced_at": "2026-10-20T18:44:25.019Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • Denver, Colorado • Tamarac, Florida + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Tamarac",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Hinsdale",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06466135"
    },
    {
      "nct_id": "NCT01093781",
      "title": "Aliskiren in Patients With Idiopathic Membranous Nephropathy",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Idiopathic Membranous Nephropathy"
      ],
      "interventions": [
        {
          "name": "Aliskiren",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 0,
      "start_date": "2010-11",
      "completion_date": "2011-12",
      "has_results": false,
      "last_update_posted_date": "2013-03-13",
      "last_synced_at": "2026-10-20T18:44:25.019Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01093781"
    },
    {
      "nct_id": "NCT02382523",
      "title": "Acthar on Proteinuria in IgA Nephropathy Patients",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "IgA Nephropathy",
        "Proteinuria"
      ],
      "interventions": [
        {
          "name": "Acthar 80 unit injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2015-02",
      "completion_date": "2020-01",
      "has_results": false,
      "last_update_posted_date": "2017-04-05",
      "last_synced_at": "2026-10-20T18:44:25.019Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02382523"
    },
    {
      "nct_id": "NCT04804566",
      "title": "Understanding Fabry Disease Therapy Choices Through the Eyes of the Patients",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Fabry Disease"
      ],
      "interventions": [
        {
          "name": "This is a non-interventional study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Amicus Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2023-03-01",
      "completion_date": "2023-11-01",
      "has_results": false,
      "last_update_posted_date": "2024-04-03",
      "last_synced_at": "2026-10-20T18:44:25.019Z",
      "location_count": 1,
      "location_summary": "Eagan, Minnesota",
      "locations": [
        {
          "city": "Eagan",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04804566"
    },
    {
      "nct_id": "NCT02010242",
      "title": "Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus With Diabetic Nephropathy"
      ],
      "interventions": [
        {
          "name": "GKT137831",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Calliditas Therapeutics AB",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 136,
      "start_date": "2013-10",
      "completion_date": "2015-03",
      "has_results": true,
      "last_update_posted_date": "2025-02-28",
      "last_synced_at": "2026-10-20T18:44:25.019Z",
      "location_count": 20,
      "location_summary": "Tucson, Arizona • Orange, California • Coral Gables, Florida + 16 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02010242"
    },
    {
      "nct_id": "NCT00343577",
      "title": "Antiproteinuric Agents and Fabry Disease",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Fabry Disease",
        "Proteinuria"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": "95 Years",
        "sex": "ALL",
        "summary": "14 Years to 95 Years"
      },
      "enrollment_count": 12,
      "start_date": "2001-01",
      "completion_date": "2006-12",
      "has_results": false,
      "last_update_posted_date": "2013-11-19",
      "last_synced_at": "2026-10-20T18:44:25.019Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00343577"
    }
  ]
}